The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Nonalcoholic fatty liver disease: treatment

비알코올성 지방간질환의 치료

  • Park, Sang-Hoon (Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine)
  • 박상훈 (한림대학교 의과대학 강남성심병원 소화기내과)
  • Published : 2010.11.01
⟨ Previous Next ⟩

Abstract

Recently, nonalcoholic fatty liver disease (NAFLD) is highly prevalent even in Korea, which has the potential to progress to cryptogenic cirrhosis and hepatocellular carcinoma. It is not only regarded as a hepatic component of the metabolic syndrome but also as an independent risk factor and a marker for increase in cardiovascular disease. We should keep in mind the NAFLD is a "treatable and have to treat" disease to prevent early death from liver and cardiovascular complications. Weight loss via lifestyle modification remains the most common and fundamental therapy advocated for reducing hepatic lipid in NAFLD. There is increasing evidence that exercise or physical activity beneficially modulates liver fat independent of weight loss. Although reduced total calorie intake potentially plays a role in the treatment of NAFLD, dietary macronutrient composition may also play a role. Low-carbohydrate and low-fructose diets are of particular benefit to reduce steatosis and improve biochemical tests. Polyunsaturated fatty acid (n3-PUFA) and monounsaturated fatty acid (MUFA) may play a protective role against increase liver fat. Limitation of Saturated fat and trans-fatty acids intake is very recommendable. Even lifestyle modifications continued to be the cornerstone of therapy in NAFLD, some insulin-sensitizing drug may be a more effective means in the treatment of NAFLD. Vitamin E and statins have demonstrated promising initial results in improving liver enzymes or features of liver histology. Bariatric surgery is very useful treatment option for morbidly obese NAFLD patients. However, weight loss medication is not recommended which have shown varying degrees of side effects for the treatment of NAFLD.

Keywords

References

  1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960-967, 2003 https://doi.org/10.1111/j.1572-0241.2003.07486.x
  2. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17-26, 2001 https://doi.org/10.1055/s-2001-12926
  3. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 21:138-143, 2006 https://doi.org/10.1111/j.1440-1746.2005.04086.x
  4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820-1832, 2010 https://doi.org/10.1002/hep.23594
  5. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 44:1190-1194, 2009 https://doi.org/10.1007/s00535-009-0112-0
  6. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 45:86-94, 2010 https://doi.org/10.1007/s00535-009-0128-5
  7. Oh KC, Park SH, Park JC, Jin DK, Park CS, Kim KO, Jang HJ, Lee JY, Park CH, Han TH, Yoo KS, Kim JH, Kim DJ, Lee MS, Park CK. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol 45:45-51, 2005
  8. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873, 2006 https://doi.org/10.1002/hep.21327
  9. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546, 2005 https://doi.org/10.2337/diabetes.54.12.3541
  10. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 164:2169-2175, 2004 https://doi.org/10.1001/archinte.164.19.2169
  11. Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, Kim CH, Lee HS. Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis. Korean J Hepatol 14:77-88, 2008 https://doi.org/10.3350/kjhep.2008.14.1.77
  12. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341-1350, 2010 https://doi.org/10.1056/NEJMra0912063
  13. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, Simard S, Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135:48-58, 2004 https://doi.org/10.1016/j.surg.2003.10.003
  14. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114:842-845, 1998 https://doi.org/10.1016/S0016-5085(98)70599-2
  15. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sclsitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196, 2005 https://doi.org/10.1210/jc.2004-1959
  16. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103-107, 1997 https://doi.org/10.1016/S0168-8278(97)80287-5
  17. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99:1408-1413, 1990
  18. Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, Konigsrainer A, Konigsrainer I, Krober S, Niess A, Fritsche A, Haring HU, Stefan N. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:1281-1288, 2009 https://doi.org/10.1136/gut.2008.151977
  19. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53:413-419, 2004 https://doi.org/10.1136/gut.2003.027581
  20. Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 107:1755-1767, 2007 https://doi.org/10.1016/j.jada.2007.07.017
  21. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multi-disciplinary approach. Hepatology 47:746-754, 2008
  22. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 98:926-930, 2003 https://doi.org/10.1111/j.1572-0241.2003.07375.x
  23. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:639-644, 2006 https://doi.org/10.1016/j.cgh.2006.02.004
  24. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:80-86, 2009 https://doi.org/10.1002/hep.22575
  25. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134, 2005 https://doi.org/10.1056/NEJMoa044537
  26. Banasch M, Goetze O, Schmidt WE, Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int 27:1152-1155, 2007 https://doi.org/10.1111/j.1478-3231.2007.01555.x
  27. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study. Eur Heart J 29:1761-1771, 2008 https://doi.org/10.1093/eurheartj/ehn076
  28. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775, 2006 https://doi.org/10.1001/jama.295.7.761
  29. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39:1647-1654, 2004 https://doi.org/10.1002/hep.20251
  30. O'Brien PE, Dixon JB, Laurie C, Skinner S, Proietto J, McNeil J, Strauss B, Marks S, Schachter L, Chapman L, Anderson M. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 144:625-633, 2006 https://doi.org/10.7326/0003-4819-144-9-200605020-00005
  31. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, Romon M, Pattou F. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137:532-540, 2009 https://doi.org/10.1053/j.gastro.2009.04.052
  32. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 17:486-492, 2007 https://doi.org/10.1007/s11695-007-9086-2
  33. Chapman AE, Kiroff G, Game P, Foster B, O'Brien P, Ham J, Maddern GJ. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery 135:326-351, 2004 https://doi.org/10.1016/S0039-6060(03)00392-1
  34. de Almeida SR, Rocha PR, Sanches MD, Leite VH, da Silva RA, Diniz MT, Diniz Mde F, Rocha AL. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 16:270-278, 2006 https://doi.org/10.1381/096089206776116462
  35. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136:1552-1560, 2009 https://doi.org/10.1053/j.gastro.2009.01.048
  36. Okita M, Hayashi M, Sasagawa T, Takagi K, Suzuki K, Kinoyama S, Ito T, Yamada G. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 17:542-547, 2001 https://doi.org/10.1016/S0899-9007(01)00543-3
  37. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100:1072-1081, 2005 https://doi.org/10.1111/j.1572-0241.2005.41334.x
  38. Hollingsworth KG, Abubacker MZ, Joubert I, Allison ME, Lomas DJ. Low-carbohydrate diet induced reduction of hepatic lipid content observed with a rapid non-invasive MRI technique. Br J Radiol 79:712-715, 2006 https://doi.org/10.1259/bjr/23166141
  39. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, Yamaji R, Inui H, Fukusato T, Yamanouchi T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 139:2067-2071, 2009 https://doi.org/10.3945/jn.109.105858
  40. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48:993-999, 2008 https://doi.org/10.1016/j.jhep.2008.02.011
  41. Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, Grosovski M. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 22:811-816, 2008
  42. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51:1961-1971, 2010 https://doi.org/10.1002/hep.23535
  43. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A, Yki-Jarvinen H. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 90:2804-2809, 2005 https://doi.org/10.1210/jc.2004-1983
  44. Funaki M. Saturated fatty acids and insulin resistance. J Med Invest 56:88-92, 2009 https://doi.org/10.2152/jmi.56.88
  45. Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol 5:335-344, 2009 https://doi.org/10.1038/nrendo.2009.79
  46. Clarke SD. Nonalcoholic steatosis and steatohepatitis: I. molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 281:G865-G869, 2001
  47. Xu J, Cho H, O'Malley S, Park JH, Clarke SD. Dietary polyunsaturated fats regulate rat liver sterol regulatory element binding proteins-1 and -2 in three distinct stages and by different mechanisms. J Nutr 132:3333-3339, 2002
  48. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr 67:S577-S582, 1998
  49. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 poly-unsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 40:194-199, 2008 https://doi.org/10.1016/j.dld.2007.10.003
  50. Paniagua JA, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 30:1717-1723, 2007 https://doi.org/10.2337/dc06-2220
  51. Tremblay F, Lavigne C, Jacques H, Marette A. Role of dietary proteins and amino acids in the pathogenesis of insulin resistance. Annu Rev Nutr 27:293-310, 2007 https://doi.org/10.1146/annurev.nutr.25.050304.092545
  52. Sullivan S. Implications of diet on nonalcoholic fatty liver disease. Curr Opin Gastroenterol 26:160-164, 2010 https://doi.org/10.1097/MOG.0b013e3283358a58
  53. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130:2023-2030, 2006 https://doi.org/10.1053/j.gastro.2006.03.019
  54. Perseghin G, Lattuada G, De Cobelli F, Ragogna F, Ntali G, Esposito A, Belloni E, Canu T, Terruzzi I, Scifo P, Del Maschio A, Luzi L. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 30:683-688, 2007 https://doi.org/10.2337/dc06-2032
  55. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with non-alcoholic fatty liver disease. Hepatology 50:68-76, 2009 https://doi.org/10.1002/hep.22940
  56. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, George J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50:1105-1112, 2009 https://doi.org/10.1002/hep.23129
  57. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 52:370-381, 2010
  58. Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of Sports Medicine Position Stand: appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 41:459-471, 2009
  59. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48:1791-1798, 2008 https://doi.org/10.1002/hep.22525
  60. Burgomaster KA, Howarth KR, Phillips SM, Rakobowchuk M, Macdonald MJ, McGee SL, Gibala MJ. Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans. J Physiol 586:151-160, 2008
  61. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122:1924-1940, 2002 https://doi.org/10.1053/gast.2002.33666
  62. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017, 2003
  63. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004 https://doi.org/10.1002/hep.20012
  64. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307, 2006 https://doi.org/10.1056/NEJMoa060326
  65. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46:424-429, 2007 https://doi.org/10.1002/hep.21661
  66. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51:445-453, 2010 https://doi.org/10.1002/hep.23270
  67. Harrison SA. Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? Hepatology 51:366-369, 2010 https://doi.org/10.1002/hep.23473
  68. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
  69. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6:998-1003, 2000 https://doi.org/10.1038/79697
  70. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358:893-894, 2001 https://doi.org/10.1016/S0140-6736(01)06042-1
  71. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20:23-28, 2004
  72. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37-46, 2005 https://doi.org/10.7326/0003-4819-142-1-200501040-00110
  73. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675-1685, 2010 https://doi.org/10.1056/NEJMoa0907929
  74. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:770-778, 2004 https://doi.org/10.1002/hep.20092
  75. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52:472-479, 2010
  76. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 28:396-406, 2008 https://doi.org/10.1055/s-0028-1091984
  77. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47:135-141, 2007 https://doi.org/10.1016/j.jhep.2007.02.013
  78. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 11:597-613, 2007 https://doi.org/10.1016/j.cld.2007.06.010
  79. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46:1453-1463, 2007 https://doi.org/10.1002/hep.21848
  80. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40:1222-1225, 2004 https://doi.org/10.1002/hep.20420